Company Overview and News
April 19 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Thursday: ** Japan’s Takeda Pharmaceutical is in negotiations with Shire after making a third takeover bid worth around $61 billion that was rejected by the London-listed rare diseases drugmaker. ** Brazil’s state-run oil company Petroleo Brasileiro SA is considering selling 60 percent stakes in two regional blocks comprising four refineries, and keeping full ownership of nine other units, it said in a securities filing.
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Industrial and commodities-focused stocks also led the pack in London, Paris, Frankfurt and Milan though the pan-regionally STOXX 600 was showing some signs of fatigue after a two-day rally had taken it to a six-week high.
3:30 pm Market Closing: Benchmark indices closed higher despite crude oil prices, backed by metals, technology and FMCG stocks.
"The state-of-the-art facility enables Honeywell to provide enhanced expertise and training capabilities to customers and expand its production range," the company said.
Sunil Munjal of Hero Enterprise and Arvind, Mohit Burman of Dabur, who have jointly entered the fray to take control of Fortis Healthcare, on Thursday sweetened their offer and agreed to invest Rs 1,500 crore, an upward revision of Rs 250 crore from their previous offer.
1:52 pm Market Update: The market continued to trade mildly higher, with support from metals, technology and FMCG stocks. It shrugged off higher crude oil prices.
Shares of Indian Oil Corp Ltd declined as much as 4 per cent to Rs 158.2, lowest since later December 2016. - KSL
Metal stocks gained as LME aluminium hit near 7-year high. The metal index surged as much as 3.6 per cent to highest since March 6.
12:55 pm Buzzing: Allied Digital was locked at 10 percent upper circuit after one-time settlement of its dues to State Bank of India for Rs 60.34 crore.
ACC reported better-than-expected quarter as cost pressure from high petroleum coke prices, and higher freight was not fully reflected,
Shares of Mindtree jumped nearly 4 per cent to hit a record high of Rs 899 on strong Q4 profit.
774 crore for the construction of third rail line between Jimidipeta and Gotlam on East Coast Railway on engineering, procurement and construction (EPC) basis.
Fortis, which runs about 30 hospitals across India, has become the target of a takeover battle, with Malaysia's IHH Healthcare Bhd, local rival Manipal Health Enterprises Pvt Ltd and China's Fosun International Ltd vying for the cash-strapped company.
9:59 am Buzzing: Mindtree share price gained 3 percent after the company reported a 28.8 percent sequential growth in profit at Rs 182.2 crore and6.3 percent in revenue at Rs 1,464 crore for the quarter ended March 2018.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...